Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

The development, usability, and reliability of the Electronic Patient Visit Assessment (ePVA) for head and neck cancer.

Van Cleave JH, Fu MR, Bennett AV, Persky MS, Li Z, Jacobson A, Hu KS, Most A, Concert C, Kamberi M, Mojica J, Peyser A, Riccobene A, Tran A, Persky MJ, Savitski J, Liang E, Egleston BL.

Mhealth. 2019 Jul 29;5:21. doi: 10.21037/mhealth.2019.06.05. eCollection 2019.

2.

Evaluation of chemical stability of polymers of XIENCE everolimus-eluting coronary stents in vivo by pyrolysis-gas chromatography/mass spectrometry.

Kamberi M, Pinson D, Pacetti S, Perkins LEL, Hossainy S, Mori H, Rapoza RJ, Kolodgie F, Virmani R.

J Biomed Mater Res B Appl Biomater. 2018 Jul;106(5):1721-1729. doi: 10.1002/jbm.b.33979. Epub 2017 Sep 7.

PMID:
28884951
3.

Echogenicity as a surrogate for bioresorbable everolimus-eluting scaffold degradation: analysis at 1-, 3-, 6-, 12- 18, 24-, 30-, 36- and 42-month follow-up in a porcine model.

Campos CM, Ishibashi Y, Eggermont J, Nakatani S, Cho YK, Dijkstra J, Reiber JH, Sheehy A, Lane J, Kamberi M, Rapoza R, Perkins L, Garcia-Garcia HM, Onuma Y, Serruys PW.

Int J Cardiovasc Imaging. 2015 Mar;31(3):471-82. doi: 10.1007/s10554-015-0591-4. Epub 2015 Jan 28.

4.

Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobalt-chromium XIENCE V stent in a porcine coronary artery model.

Otsuka F, Pacheco E, Perkins LE, Lane JP, Wang Q, Kamberi M, Frie M, Wang J, Sakakura K, Yahagi K, Ladich E, Rapoza RJ, Kolodgie FD, Virmani R.

Circ Cardiovasc Interv. 2014 Jun;7(3):330-42. doi: 10.1161/CIRCINTERVENTIONS.113.000990. Epub 2014 Jun 3.

PMID:
24895447
5.
6.

Setting acceptance criteria for validation of analytical methods of drug eluting stents: Minimum requirements for analytical variability.

Kamberi M, Garcia H, Feder DP, Rapoza RJ.

Eur J Pharm Sci. 2011 Feb 14;42(3):230-7. doi: 10.1016/j.ejps.2010.11.013. Epub 2010 Nov 30.

PMID:
21126583
7.

Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial.

Onuma Y, Serruys PW, Perkins LE, Okamura T, Gonzalo N, García-García HM, Regar E, Kamberi M, Powers JC, Rapoza R, van Beusekom H, van der Giessen W, Virmani R.

Circulation. 2010 Nov 30;122(22):2288-300. doi: 10.1161/CIRCULATIONAHA.109.921528. Epub 2010 Oct 25.

PMID:
20975003
8.

A novel accelerated in vitro release method for biodegradable coating of drug eluting stents: Insight to the drug release mechanisms.

Kamberi M, Nayak S, Myo-Min K, Carter TP, Hancock L, Feder D.

Eur J Pharm Sci. 2009 Jun 28;37(3-4):217-22. doi: 10.1016/j.ejps.2009.02.009. Epub 2009 Feb 27.

PMID:
19491008
9.

Quantification of apolipoprotein A-I mimetic peptide D-4F in rabbit plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

Hu X, Kamberi M.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jul 1;877(20-21):1946-50. doi: 10.1016/j.jchromb.2009.04.044. Epub 2009 May 13.

PMID:
19481508
10.

A sensitive high-throughput HPLC assay for simultaneous determination of everolimus and clobetasol propionate.

Kamberi M, Fu K, Lu J, Chemaly GM, Feder D.

J Chromatogr Sci. 2008 Jan;46(1):23-9.

PMID:
18218184
11.
12.

Analysis of non-covalent aggregation of synthetic hPTH (1-34) by size-exclusion chromatography and the importance of suppression of non-specific interactions for a precise quantitation.

Kamberi M, Chung P, DeVas R, Li L, Li Z, Ma XS, Fields S, Riley CM.

J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Oct 15;810(1):151-5.

PMID:
15358319
13.

A validated, sensitive HPLC method for the determination of trace impurities in acetaminophen drug substance.

Kamberi M, Riley CM, Ma Sharon X, Huang CW.

J Pharm Biomed Anal. 2004 Jan 27;34(1):123-8.

PMID:
14738926
16.

Determination of grepafloxacin in plasma and urine by a simple and rapid high-performance liquid chromatographic method.

Kamberi M, Kamberi P, Nakano S.

J Chromatogr B Biomed Sci Appl. 2000 May 12;741(2):295-300.

PMID:
10872599
17.

The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.

Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S.

Br J Clin Pharmacol. 2000 Feb;49(2):98-103.

18.

Determination of sparfloxacin in plasma and urine by a simple and rapid liquid chromatographic method.

Kamberi M, Kamberi P, Hajime N, Uemura N, Nakamura K, Nakano S.

Ther Drug Monit. 1999 Aug;21(4):411-5.

PMID:
10442694
19.

Simultaneous determination of grepafloxacin, ciprofloxacin, and theophylline in human plasma and urine by HPLC.

Kamberi M, Hajime N, Kamberi P, Uemura N, Nakamura K, Nakano S.

Ther Drug Monit. 1999 Jun;21(3):335-40.

PMID:
10365649
20.

Influences of urinary pH on ciprofloxacin pharmacokinetics in humans and antimicrobial activity in vitro versus those of sparfloxacin.

Kamberi M, Tsutsumi K, Kotegawa T, Kawano K, Nakamura K, Niki Y, Nakano S.

Antimicrob Agents Chemother. 1999 Mar;43(3):525-9.

21.

Sparfloxacin pharmacokinetics in healthy volunteers: the influence of acidification and alkalinization.

Kamberi M, Kotegawa T, Tsutsumi K, Nakamura K, Nakano S.

Eur J Clin Pharmacol. 1998 Oct;54(8):633-7.

PMID:
9860151
22.

Determination of ciprofloxacin in plasma and urine by HPLC with ultraviolet detection.

Kamberi M, Tsutsumi K, Kotegawa T, Nakamura K, Nakano S.

Clin Chem. 1998 Jun;44(6 Pt 1):1251-5.

Supplemental Content

Loading ...
Support Center